Clinical Trial Update: Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase II study evaluating DCVAC/PCa added to standard chemotherapy for metastatic castration-resistant prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• DCVAC/PCa (dendritic cell vaccine DCVAC/PCa)

Snippet

Sponsor: SOTIO a.s. | Conditions: Prostate Cancer, Prostate Cancer Metastatic | Phase 2 | Status: COMPLETED